Upgrade to SI Premium - Free Trial

Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected

July 6, 2026 6:43 AM
Cantor Fitzgerald analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $265.00 (from $240.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change